1024 27 210093 210002 1 2 1 * 2 * 1 1 1 1 3 4 1990 1 2013 12 27 27 25 2 NK /T 2 B 25 MALT 13 LPL 4 MCL 3 SLL 2 EMP 3 13 B MALT 8 MCL 3 SLL 2 R739. 7 A 1009-0460 2014 11-1024-06 Clinical and pathological features of ocular adnexal lymphoma in 27 patients ZHU Jing QIN Shukui SHI Yi WANG Lin CHEN Yingxia HUA Haiqing LIU Xiufeng LI Guimei ZHANG Zhiqiang. Department of Respiratory Medicine Medical School Nanjing University Nanjing General Hospital of Nanjing Military Command Nanjing 210093 PLA Cancer Center Bayi Hospital Nanjing 210002 China Corresponding author SHI Yi E-mail shiyi56@ 126. com QIN Shukui E-mail qinsk@ csco. org. cn Abstract Objective To explore the clinical manifestations and pathological features of ocular adnexal lymphoma. Methods The clinical and pathological information of 27 patients diagnosed as ocular adnexal lymphoma in 81 Hospital of PLA by pathological examination from January 1990 to December 2013 were collected and the pathological features of the disease were analyzed retrospectively. Results The lesions were limited to the orbital area in 25 cases and the rest 2 cases were secondary to the lymphoma of other organs. The pathological diagnosis in all the cases was non-hodgkin's lymphoma of which T cell in 2 cases and B cell lymphoma in 25 cases including mucosa-associated lymphoid tissue MALT lymphoma 13 cases lymphoplasmacytic lymphoma LPL 4 cases mantle cell lymphoma MCL 3 cases small lymphocytic lymphoma SLL 2 cases extramedullary plasmacytoma EMP 3 cases. There were 13 cases originally diagnozed as small B cell lymphoma. They were clearly diagnozed as 8 MALT lymphoma 3 MCL and 2 SLL by immunohistochemical staining. Conclusion Clear classification can provide more useful suggestions about the choice of treatment and prognosis for the patients. Key Words Ocular adnexal Lymphoma Pathology Clinical treatment 11% 1-2 1 210002 2 210093 3 210002 4 210002 * E-mail shiyi56@ 126. com qinsk@ csco. org. cn
1025 4μm HE 1990 En Vision 1 2013 12 27 1 1. 1 27 CD43 CD38 18 9 2 1 18 ~ 75 50 1. 1. 1 27 NK /T Ki-67 25 2 13 3 24 15 9 24 13 3 CyclinD1 Ki-67 CD20 4 7 3 CD79α CD3 CD5 CD23 CD10 CD43 CD38 1 8 CD138 CD45RO CD56 Bcl-2 4 1 2 4 % 5 1 8 1. 1. 2 <5% - 5% ~ 20% + 21% ~ 50% + + >50% +++ Ki-67 1. 2. 2 27 14 3 12 CT 5 MRI 3 CT CT 3 4 MRI T1WI T2WI 1. 2 1. 2. 1 CD20 CD79α CD3 T B B CD5 CD23 CD10 CyclinD1 CD38 CD138 T CD45RO CD56 T 100 1 A CT B CT C MRI T1WI D MRI T2 E MRI T1WI F MRI T2WI G MRI H MRI 1 CT MRI
1026 2 2. 1 27 + 3G CD43 CD10 - Ki-67 5% 4. 5cm 2. 7cm 2. 3cm 1cm 0. 4cm 0. 3cm 5 CD79α CD5 - CD3 CD56 CD45RO + 2 1 3H Ki-67 5% ~ 20% 1 2. 4 27 B 2 2. 2 HE 2008 WHO 27 MALT HE 13 B MALT 8 MCL 3 SLL MALT 2 1 2D LPL HE 1 27 2E MCL HE % / MALT 13 2F 48. 1 11 /2 LPL 4 14. 8 2 /2 2G MCL 3 11. 1 1 /2 SLL HE SLL 2 7. 4 2 /0 EMP NK /T 3 2 11. 1 7. 4 1 /2 1 /1 2H 2. 5 27 8 EMP HE 1 + 11 + 2I NK /T 2 + 1 + 1 HE + + 2 + + 1 2J 2. 3 1 13 MALT CD20 + 3A CD79α + Bcl-2 + CD5 - CD23 - CD10 - CyclinD1-27 Ki-67<5% 6 5% ~ 20% 7 2 4 LPL CD20 + 3B CD79α + CD38 + 2014 4 21 CD3 CD5 CD23 CD10 CyclinD1-3 CD43 17 4 + 1 CD43 - Ki-67 10% 1 3 < 5% 3 3 MCL CD20 + CD79α + CD3 - CD5 + 3C CD43 + CyclinD1 + 3D CD10-2 CD23 + 1 CD23 - Ki-67 5% ~ 20% 2 1 < 5% 4 2 SLL CD20 + 3E 30% 5 3 EMP 2 CD20-1 CD20 + CD79α + CD3 - CD138 CD38 ~ 30% 6 2 NK /T CD20 25 92. 6% T 2 7. 4% CHOP VM-26 VP- 16 Me-CCNu EMP 28 1 MALT 3 50 ~ 70 CD79α + CD3 - CD5 + 3F CD23 + CD10 CycliD1 - Ki-67 5% 1 1
1027 A B C D MALT 200 E LPL 200 F MCL 40 G MCL 200 H SLL 200 I EMP 200 J NK /T 400 2 HE A MALT CD20 200 B LPL CD20 200 C MCL CD5 400 D MCL CyclinD1 400 E SLL CD20 200 F SLL CD5 200 G EMP CD138 200 H NK /T CD45RO 400 3 En Vision 4-5 14 15 50% 1% 6 NK /T 1 /3 42% ~ 92% 8 ~ 29 7 7-8 1 MALT B 2 3 CT MRI 4 MALT
1028 MALT 5 83% / 50% 8% 18 2013 6 FDA 9 MCL MCL 10 Isaacson 11 MALT SLL CLL MALT SLL CD10 CD5 CyclinD1 12 MALT B CLL /SLL 19 CLL /SLL CD19 CD20 CD22 NCCN CD79α CD43 CD5 CD23 CD10 CyclinD1 MALT 20 ~ 30Gy 80% EMP MALT EMP 30Gy CD20 CD38 CD138 EMA CD10 CD20 CD43 PAX5 13 COP /CHOP EMP λ CR κ λ 20 Barbara 14 4 3 NK /T 1 EBV CD56 NK /T NCCN MALT LPL 2% NK /T 5% 15 LPL WM IgM >3g /Dl LPL B CD45RO CD38 + EMP CD56 CD20 CD79a CD5 Ki-67 CD138 - MCL t 11 14 q13 q32 CyclinD1 B MALT 5% ~ 10% 3 ~ 5 16 MCL HE CyclinD1 MCL 1 Shields JA Shields CL Scartozzi R. Survey of 1264 patients with MCL 17 2 Decaudin D orbital tumors and simulating lesions the 2002 Montgomery Lecture part 1 J. Ophthalmology 2004 111 5 997-1008. de Cremoux P Vincent-Salomon A et al. Ocular
1029 adnexal lymphoma a review of clinicopathologic features and treatment options J. Blood 2006 108 5 1451-1460. 3 Coupland SE Hellmich M Auw-Haedrich C et al. Prognostic value of cell-cycle markers in ocular adnexal lymphoma an assessment of 230 cases J. Graefe's Archive for Clinical and Experimental Ophthalmology 2004 242 2 145-130. 4 Judith AF Claire YF Lawrence Z et al. Lymphoma of the ocular adnexa a study of 353 cases J. Am J Surg Pathol 2007 31 2 170-184. 5. MALT B J. 2007 27 2 116-119. 6. 1 J. 2012 2 4-6. 7 Sagoo MS Mehta H Swampillai AJ et al. Primary intraocular lymphoma J. Surv Ophthalmol 2014 59 503-516. 8 Woolf DK Ahmed M Plowman PN. Primary lymphoma of the ocular adnexa orbital lymphoma and primary intraocular lymphoma J. Clin Oncol 2012 24 5 339-344. 9. primary ocular adnexal lymphoma J. Oncologist 2013 18 7 J. 2011 1 97-99. 876-884. 10. MALT 19. M. J. 2012 6 1526-1530. 11 Isaacson PG. Lymphomas of mucosa-associated lymphoid tissue malt J. Histopathology 1990 16 6 617-619. 5 70-74. 12. MALT 96 144. B J. 2012 13. MALT J. 2012 4 912-916. 14 Barbara K Markus R. Antibiotic therapy in nongastrointestinal malt lymphoma a review of the literature J. Blood 2013 122 8 1350-1357. 15 Sarah E Lothar K Henri-Jacques D et al. Lymphoproliferative lesions of the ocular adnexa analysis of 112 cases J. Ophthalmology 1998 105 8 1430-1441. 16. J. 2013 20 301-304. 17 Elham VK Benjamin HD Mingyi C et al. Mantle Cell Lymphoma and Involvement of the Orbit and Ocular Adnexa J / OL. Case Rep Pathol 2013 2014-07-20. http / /www. ncbi. nlm. nih. gov / pubmed /23691402. 18 Maurilio P Silvia G Giada L et al. A reappraisal of the diagnostic and therapeutic management of uncommon histologies of 2010 161. 20. 43 J. 2006 1 93-2014-08-06 2014-09-25